Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

Results showed that a dry powder inhaler loaded with umeclidinium and vilanterol produced a 14% lower risk of moderate or severe COPD flare-ups, compared to a metered-dose inhaler loaded with ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for about three months, a new study has revealed. This research by The University ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Please provide your email address to receive an email when new articles are posted on . Several clinicians expressed concern about inhaler costs for those with COPD in January. AstraZeneca, Boehringer ...

Add Yahoo as a preferred source to see more of our stories on Google. Inhalers that provide fast-acting treatment for people with certain respiratory conditions are contributing to greenhouse gas ...

Please provide your email address to receive an email when new articles are posted on . Invited patients had 32% of days covered for maintenance inhalers, whereas control patients had a smaller ...

Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new UCLA Health study — the largest to date quantifying inhaler-related ...

Inhalers that provide fast-acting treatment for people with certain respiratory conditions are contributing to greenhouse gas emissions, which can worsen both climate change and the conditions ...